An In-Depth Look at Multiple Myeloma: Causes, Symptoms, and Treatment Options

This article provides a comprehensive overview of multiple myeloma, covering its causes, symptoms, diagnosis, and treatment options. It discusses factors influencing prognosis and the importance of ongoing research for personalized treatment, highlighting the disease’s impact on health and survival rates. Effective management and early diagnosis are crucial for improving patient quality of life and extending survival time.

Overview of Multiple Myeloma

Multiple myeloma

Also known as plasma cell cancer, this disease is characterized by the uncontrolled growth of plasma cells within the bone marrow. Normally responsible for producing antibodies, abnormal plasma cells multiply excessively, causing symptoms like bone pain, anemia, bleeding, infections, and amyloidosis. Despite treatment, many patients experience relapses. The causes are not fully identified but may include genetic factors, obesity, alcohol intake, radiation, and chemical exposure. These malignant cells produce abnormal antibodies that thicken the blood and can damage kidneys.

This disease results in tumor formations within the bone marrow's soft tissues. Multiple tumors define the condition. Diagnosis involves blood and urine tests for abnormal protein levels, bone marrow examinations, imaging studies for bone lesions, and elevated calcium levels. Although treatable, it remains incurable with potential for recurrence. Therapies such as steroids, thalidomide, chemotherapy, stem cell transplantation, and lenalidomide can extend survival, often by about five years. In the USA, over 11,000 deaths annually are attributed to multiple myeloma or its relapse.

Relapses occur when initial treatments lose effectiveness or the disease advances without response, complicating management. It can affect various organs, causing symptoms like:

Bone pain, especially in the spine and ribs, often worsened by activity, indicating possible fractures.

Anemia due to bone marrow infiltration reducing red blood cell production.

The secretion of abnormal antibodies that can damage kidneys.

Infections such as pneumonia, with symptoms like fatigue, confusion, neurological issues, and numbness in limbs.

Risk factors include monoclonal gammopathy, undiagnosed multiple myeloma, obesity, genetic predisposition, and inherited protein hyperphosphorylation, more prevalent among African Americans. Resistance and disease recurrence depend on tumor variability and previous treatments, with approaches including treatment adjustments, stem cell therapy, and newer drugs like bortezomib, thalidomide, and pomalidomide. Kidney complications might require dialysis. Oral agents such as ixazomib and daratumumab are also utilized. Palliative care is vital for symptom relief. Survival rates have improved, with about 35% surviving five years, though outlook varies with age and disease severity. Genetic testing at specialized centers aids in risk assessment. Current research aims to customize therapies based on genetic profiles to enhance patient outcomes.